Abeona Therapeutics ABEO 深 滬
等待開盤 08-30 09:30:00 美东时间
6.83
-0.050
-0.73%
華盛通- 最 高6.95
- 今 開6.93
- 成交量 40.48万股
- 最 低 6.735
- 昨 收 6.88
- 總市值 3.49亿
- 52周最高 7.5401
- 市盈率 靜 --
- 換手率 0.79%
- 52周最低 3.9328
- 委 比 -59.94%
- 總股本 5115.67万
- 歷史最高 750.00
- 量 比 0.67
- 振 幅 3.13%
- 歷史最低 2.19
- 每 手 1
- 風險率 0.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Abeona Therapeutics Inc. announced that its management team will participate in two upcoming investor conferences in September 2025: a fireside chat at the Cantor Global Healthcare Conference on September 4 and a presentation at the H.C. Wainwright Global Investment Conference on September 9. Both events will be webcast live and available for replay on the company’s website. Abeona, a biopharmaceutical company, develops cell and gene therapies fo...
08-29 11:30
Krystal Biotech adjusts pipeline to prioritize inhaled antitumor agent
Krystal Biotech (NASDAQ:KRYS) announced Thursday a revamped product pipeline after a decision to prioritize studies for an inhaled version of its antitumor candidate KB707 targeted at non-small cell l...
08-22 00:59
Oppenheimer Maintains Outperform on Abeona Therapeutics, Raises Price Target to $20
Oppenheimer analyst Andreas Argyrides maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and raises the price target from $19 to $20.
08-15 22:35
快讯 | Abeona Therapeutics, Inc.：Oppenheimer 将目标价从 19 美元上调至 20 美元
Abeona Therapeutics, Inc. : Oppenheimer Raises Target Price to $20 From $19
08-15 20:12
Abeona Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
Abeona Therapeutics shares are trading higher after the company reported better...
08-14 22:14
Abeona Therapeutics Q2 EPS $1.71 Beats $(0.39) Estimate
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly earnings of $1.71 per share which beat the analyst consensus estimate of $(0.39) by 543.01 percent. This is a 757.69 percent increase over losses of $(0.26) per share
08-14 19:40
AscellaHealth Partnership With Abeona Therapeutics Highlights The Launch Commercialization Of ZEVASKYN, An FDA-Approved Cell-Based Gene Therapy
BERWYN, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, highlights the value of its HUB partnership with Abeona
07-29 22:04
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
Lucile Packard Children’s Hospital Stanford is now ready to treat patients with ZEVASKYN, a gene therapy for RDEB wounds approved by the FDA in April 2025. Developed through a decade-long collaboration between Abeona Therapeutics and Stanford Medicine, ZEVASKYN is the only therapy to treat RDEB wounds with a single application. The therapy reconstructs functional collagen in skin cells, reducing wound pain and improving quality of life. Abeona of...
07-15 11:30
Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy
MINNEAPOLIS, July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVAS...
07-14 19:00
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
07-14 18:49
